Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-24-119025
Filing Date
2024-11-14
Accepted
2024-11-14 16:32:40
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES OPPORTUNITY II, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY II, LLCATLAS VENTURE ASSOCIATES XI, L.P.ATLAS VENTURE ASSOCIATES XI, LLCATLAS VENTURE

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm2428252d5_sc13ga.htm SC 13G/A 155644
  Complete submission text file 0001104659-24-119025.txt   157661
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund XI, L.P. (Filed by) CIK: 0001708269 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1560 TRAPELO ROAD WALTHAM MA 02451
Business Address 1560 TRAPELO ROAD WALTHAM MA 02451 (781) 786-8230
Dyne Therapeutics, Inc. (Subject) CIK: 0001818794 (see all company filings)

EIN.: 364883909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91706 | Film No.: 241463259
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)